Meg Doherty

Datos Biográficos

ID6651789
NOMBREMeg Doherty
NOMBRESMeg
APELLIDODoherty
FIRMADOHERTY M
AFILIACIONESWorld Health Organization
ORCID0000-0003-2986-7129
VERIFICADOSí
TOTAL DE OBRAS7
TOTAL DE CITAS34
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN1996
AÑO MÁS RECIENTE DE PUBLICACIÓN2020
ÍNDICE H2

  • Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by Covid-19

    Open AccessBritta L Jewell, Edinah Mudimu et al.ARTICLEThe Lancet HIV2020

    BACKGROUND: The COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa. METHODS: In this modelling st…

  • Reimagining HIV service delivery

    Open AccessAnna Grimsrud, Helen Bygrave et al.ARTICLEJournal of the International AIDS…2016

    The recently updated World Health Organization (WHO) consolidated guidelines on the use of antiretroviral therapy (ART) recommending to “treat all” mark a paradigm shift in the delivery of HIV treatment: from who is eligible and when to start ART, to how to provide client-centred and high-quality care to all people living with HIV (PLHIV). As part of this shift, the new guidance includes service delivery recommendations based on a “differentiated…

  • Patient-Reported Barriers to Adherence to Antiretroviral Therapy

    Open AccessZara Shubber, Edward J Mills et al.ARTICLEPLoS Medicine2016

  • Barriers and Facilitators to Interventions Improving Retention in HIV Care

    Open AccessBrian J Hall, Ka-lon Sou et al.ARTICLEAIDS and Behavior2016

  • Gender differences in the initiation of injection drug use among young adults

    Open AccessMeg Doherty, Meg C Doherty et al.ARTICLEJournal of Urban Health2000Citada por: 7Referencias: 2

  • Prevalence and Incidence of Hepatitis C Virus Infection Among Young Adult Injection Drug Users

    RICHARD S GARFEIN, Meg Doherty et al.ARTICLEJournal of Acquired Immune…1998

    Through community-based outreach, young adult injection drug users (IDUs) were enrolled in a prospective study of the prevalence, incidence, and risk factors for hepatitis C virus (HCV) infection. Demographics and information on sexual and injecting practices were collected during semiannual interviews, and HCV infection was evaluated using a second-generation antibody assay. Of the 229 participants, 86 (37.6%) were HCV-seropositive at baseline. …

  • Viral infections in short-term injection drug users

    RICHARD S GARFEIN, David Vlahov et al.ARTICLEAmerican Journal of Public Health1996Citada por: 27Referencias: 18

    OBJECTIVES: The purpose of this study was to estimate the prevalence and correlates of four blood-borne viral infections among illicit drug injectors with up to 6 years of injecting experience. METHODS: We analyzed data from 716 volunteers recruited in 1988 and 1989. Test results for hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus, type 1 (HIV), and human T-lymphotropic virus types I and II (HTLV) were examined acro…